Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III clinical trial of Vilobelimab for Hidradenitis Suppurativa (HS)

Next Previous
Trial Profile

A phase III clinical trial of Vilobelimab for Hidradenitis Suppurativa (HS)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 21 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vilobelimab (Primary)
  • Indications Hidradenitis suppurativa
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 17 Mar 2022 According to an InflaRx media release, the FDA no longer recommends that the Company use the Hidradenitis Suppurativa Clinical Response Score (HiSCR) as the primary endpoint for the chosen patient population but gives recommendations related to implementation of the modified HiSCR (mHiSCR).
    • 28 Feb 2022 According to an InflaRx media release, given the unexpected details of the feedback from the FDA, InflaRx will pause activities related to the Phase III trial. The Company will seek to clarify the advice received and determine next steps, which will be communicated accordingly. The FDA has not issued a clinical hold.
    • 28 Feb 2022 According to an InflaRx media release, the Company has received an advice letter from the U.S. Food and Drug Administration (FDA) related to its Phase III program with vilobelimab for the treatment of hidradenitis suppurativa (HS). The feedback indicates that the FDA recommends using the Hidradenitis Suppurativa Clinical Response Score (HiSCR) as the primary endpoint in the Phase III trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top